Cited by 430Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapyAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Clarke, Noel W., Armstrong, Andrew J., Thiery-Vuillemin, Antoine, Oya, Mototsugu, Shore, Neal, Loredo, Eugenia, Procopio, Giuseppe, de Menezes, Juliana, Girotto, Gustavo, Arslan, Cagatay, Mehra, Niven, Parnis, Francis, Brown, Emma, Schlürmann, Friederike, Joung, Jae Y., Sugimoto, Mikio, Virizuela, Juan A., Emmenegger, Urban, Navratil, Jiri, Buchschacher, Gary L., Poehlein, Christian, Harrington, Elizabeth A., Desai, Chintu, Kang, Jinyu, Saad, Fred·2022·NEJM Evidence

DOI 10.1056/evidoa2200043

Open this paper in CoChat — free account

Abstract

BACKGROUND: Preclinical studies and results of a phase 2 trial of abiraterone and olaparib suggest a combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) polymerase inhibitor olaparib is combined with next-generation hormonal agent abiraterone to treat metastatic castration-resistant prostate cancer (mCRPC). METHODS: We conducted a double-blind, phase 3 trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC in the first-line setting. Patients were enrolled regardless of homologous recombination repair gene mutation (HRRm) status. HRRm status was determined following enrollment by tumor tissue and circulating tumor DNA tests. Patients were randomly assigned (1:1) to receive abiraterone (1000 mg once daily) plus prednisone or prednisolone with either olaparib (300 mg twice daily) or placebo. The primary end point was imaging-based progression-free survival (ibPFS) by investigator assessment. Overall survival was among the secondary end points. RESULTS: At this planned primary analysis at the first data cutoff, median ibPFS was significantly longer in the abiraterone and olaparib arm than in the abiraterone and placebo arm (24.8 vs. 16.6 months; hazard ratio, 0.66; 95% confidence interval [CI], 0.54 to 0.81; P<0.001) and was consistent with blinded independent central review (hazard ratio, 0.61; 95% CI, 0.49 to 0.74). At this data cutoff, overall survival data were immature (28.6% maturity; hazard ratio, 0.86; 95% CI, 0.66 to 1.12; P=0.29). The safety profile of olaparib and abiraterone was consistent with the known safety profiles of the individual drugs. The most common adverse events in the abiraterone and olaparib arm were anemia, fatigue/asthenia, and nausea. CONCLUSIONS: At primary analysis at this first data cutoff, abiraterone combined with olaparib significantly prolonged ibPFS compared with abiraterone and placebo as first-line treatment for patients with mCRPC enrolled irrespective of HRRm status. (Funded by AstraZeneca and Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; ClinicalTrials.gov number, NCT03732820.)

Integrity signals

Registry

Crossref · 10.1056/evidoa2200043

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,958
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citation
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 2,007
Self-citation
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citation
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Self-citation
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Self-citation

Flagged first, then by citations

Show all 27 references

Sorted by citations

Items 101–200 of 430

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
Bowling, G. C., Swargaloganathan, P., Heintz, C., Madan, R. A., Eldhose, B., Dobi, A. L., & Chesnut, G. T. (2023) · Cancers · doi:10.3390/cancers15194904 · Cited by 13
PARP Inhibitors in Metastatic Prostate Cancer: A Comprehensive Systematic Review and Meta-analysis of Existing Evidence
Ditonno, F., Bianchi, A., Malandra, S., Porcaro, A. B., Fantinel, E., Negrelli, R., Ferro, M., Milella, M., Brunelli, M., Riccardo Autorino, B., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.12.011 · Cited by 13
Recent Advances in Genomic Approaches for the Detection of Homologous Recombination Deficiency
Kim, Y., Gulhan, D., Jin, H., Głodzik, D., & Park, P. J. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.154 · Cited by 13
Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging Trends
Thapa, B., Sarkar, N. D., Giri, S., Sharma, K., Kim, M., & Kilari, D. (2024) · Cancer Management and Research · doi:10.2147/cmar.s411023 · Cited by 13
Therapeutic implications of homologous repair deficiency testing in patients with prostate cancer (Part 2 of 2)
Serritella, A. V., Taylor, A. K., Haffner, M. C., Abida, W. M., Bryce, A. H., Karsh, L. I., Tagawa, S. T., Twardowski, P. W., Armstrong, A. J., & Lang, J. M. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00887-z · Cited by 13
Self-citation
Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
Slootbeek, P. H. J., Kloots, I. S. H., van Oort, I. M., Kroeze, L. I., Schalken, J. A., Bloemendal, H. J., & Mehra, N. (2023) · Cancers · doi:10.3390/cancers15102814 · Cited by 13
Self-citation
2023 European Society for Medical Oncology (ESMO) Congress
Chi, K. N., Canil, C., Alimohamed, N. S., Soulières, D., & Breau, R. H. (2023) · Canadian Urological Association Journal · doi:10.5489/cuaj.8688 · Cited by 13
The emerging role of PARP inhibitors in prostate cancer: A narrative review
Lobianco, L., Calvanese, G., D'Ausilio, D., Rossetti, S., Cecere, S. C., Ventriglia, J., Pisano, C., Tambaro, R., Napoli, M. D., Passarelli, A. M., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103000 · Cited by 14
Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
Inderjeeth, A., Topp, M. D., Sanij, E., Castro, E., & Sandhu, S. K. (2022) · Cancers · doi:10.3390/cancers14235922 · Cited by 12
The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer
Abdel‐Aty, H., O'Shea, L., Amos, C. L., Brown, L. C., Grist, E., Attard, G., Clarke, N. W., Cross, W. R., Parker, C. C., Parmar, M., et al. (2023) · Clinical Oncology · doi:10.1016/j.clon.2023.07.009 · Cited by 12
Self-citation
Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis
Xiong, X., Zhang, S., Zheng, W., Liao, X., Yang, J., Xu, H., Hu, S., Wei, Q., & Yang, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104286 · Cited by 12
State of the Art: Personalizing Treatment for Patients With Metastatic Castration-Resistant Prostate Cancer
Abida, W. M., Beltran, H., & Raychaudhuri, R. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473636 · Cited by 16
Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors
Maiorano, B. A., Conteduca, V., Catalano, M., Antonuzzo, L., Maiello, E., Giorgi, U. D., & Roviello, G. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104157 · Cited by 13
Therapeutic biomarkers in metastatic castration-resistant prostate cancer: does the state matter?
Slootbeek, P. H. J., Tolmeijer, S. H., Mehra, N., & Schalken, J. A. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2266482 · Cited by 12
Self-citation
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now
Shore, N. D., Nielsen, S. M., Esplin, E. D., Antonarakis, E. S., Barata, P. C., Beer, T. M., Beltran, H., Bryce, A. H., Cookson, M. S., Crawford, E. D., et al. (2024) · JCO Oncology Practice · doi:10.1200/op-24-00626 · Cited by 12
Self-citation
Treatment of metastatic castration-resistant prostate cancer: review of current evidence and synthesis of expert opinions on radioligand therapy
Poon, D. M. C., Cheung, W. S. K., Chiu, P. K., Chung, D. H. S., Kung, J. B. T., Lam, D. C. M., Leung, A. K., Ng, A. C. F., O’Sullivan, J. M., Teoh, J. Y., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1530580 · Cited by 11
Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma
Herbert, K. J., Upstill‐Goddard, R., Dreyer, S. B., Rebus, S., Initiative, A. P. C. G., Pilarsky, C. P., Mukhopadhyay, D., Lord, C. J., Genomics Innovation Alliance, Biankin, A. V., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03051-z · Cited by 11
Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology
Fatima, Y., Jobre, K. N., Gómez‐Gómez, E., Małkiewicz, B., Vlahou, A., Mokou, M., Mischak, H., Frantzi, M., & Jankowski, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157475 · Cited by 11
Targeting genomic instability in cancer
Yap, T. A., Manning, H. C., Sapra, P., Mills, G. B., & O’Connor, M. J. (2026) · Cell · doi:10.1016/j.cell.2026.03.035 · Cited by 12
Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis
Fazekas, T., Széles, Á. D., Teutsch, B., Csizmarik, A., Vékony, B., Váradi, A., Kói, T., Lang, Z., Ács, N., Kopa, Z., et al. (2022) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-022-00626-2 · Cited by 11
Predictive and prognostic biomarkers in urological tumours
Cimadamore, A., Franzese, C., Loreto, C. D., Blanca, A., Antonio Lopez-beltran, B., Crestani, A., Giannarini, G., Tan, P. H., Carneiro, B. A., El‐Deiry, W. S., et al. (2023) · Pathology · doi:10.1016/j.pathol.2023.10.016 · Cited by 12
Biomarkers for Precision Patient Selection in Cancer Therapy Approvals in the US, from 2011 to 2023
Dou, Y. N., Grimstein, C., Mascaro, J., & Wang, J. (2024) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3306 · Cited by 12
Feasibility of Next-generation Sequencing of Liquid Biopsy (Circulating Tumor DNA) Samples and Tumor Tissue from Patients with Metastatic Prostate Cancer in a Real-world Clinical Setting in Germany
Mandel, P. C., Hoeh, B., Humke, C., Döring, C., Wenzel, M., Garcia, C. C., Fuhr, N., Koll, F. J., Fassl, A., Tilki, D., et al. (2024) · European Urology Focus · doi:10.1016/j.euf.2024.02.007 · Cited by 10
RNASEH2B loss and PARP inhibition in advanced prostate cancer
Carmichael, J. A., Figueiredo, I., Gürel, B., Beije, N., Yuan, W., Rekowski, J., Seed, G., Carreira, S., Bertan, C. M., de la Maza, M. D. F., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178278 · Cited by 10
PARP inhibitors alone or in combination for prostate cancer
de la Maza, M. D. F., Perez‐Gracia, J. L., López, B. M., & Castro, E. (2024) · Therapeutic Advances in Urology · doi:10.1177/17562872241272929 · Cited by 12
A Prostate-Specific Membrane Antigen-Targeting Small Molecule–Drug Conjugate Strategy to Overcome the Hematological Toxicity of Olaparib
Chen, Q., Wu, Z., Zhu, H., Zhang, F., Yu, Y., & Chen, W. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01910 · Cited by 10
CRISPR/Cas9 screens identify LIG1 as a sensitizer of PARP inhibitors in castration-resistant prostate cancer
Fracassi, G., Lorenzin, F., Orlando, F., Gioia, U., D’Amato, G., Casaramona, A. S., Cantore, T., Prandi, D., Santer, F. R., Klocker, H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179393 · Cited by 11
Next-Generation Sequencing in Oncology—A Guiding Compass for Targeted Therapy and Emerging Applications
Gales, L. N., Păun, M.-A., Butnariu, I., Simion, L., Manolescu, L. S. C., Trifanescu, O. G., & Anghel, R. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073123 · Cited by 12
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation
Fred Saad, C., Armstrong, A. J., Shore, N. D., George, D. J., Oya, M., Sugimoto, M., McKay, R. R., Hussain, M., & Clarke, N. W. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01146-4 · Cited by 15
Self-citation
Germline Testing for Prostate Cancer Patients: Evidence‐Based Evaluation of Genes Recommended by NCCN Guidelines
Xu, J., Lu, J. Z., Gielzak, M., Zheng, S. L., Lu, L., Wei, J., Cornell, B., Shi, Z., Wang, Q., Tran, H., et al. (2025) · The Prostate · doi:10.1002/pros.24918 · Cited by 10
New frontiers in prostate cancer treatment from systemic therapy to targeted therapy
Nouruzi, S., Kobelev, M., Tabrizian, N., Gleave, M. E., & Zoubeidi, A. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00282-8 · Cited by 13
Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis
Fallara, G., Belladelli, F., Robesti, D., Raggi, D., Nocera, L., Marandino, L., Galsky, M. D., Montorsi, F., Malavaud, B. A., Ploussard, G., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103801 · Cited by 10
Contextualizing Olaparib and Abiraterone in the Current Treatment Landscape for Metastatic Castration-resistant Prostate Cancer
Fallara, G., Robesti, D., Raggi, D., Montorsi, F., Necchi, A., Cooperberg, M. R., Malavaud, B. A., Ploussard, G., & Martini, A. (2023) · European Urology Open Science · doi:10.1016/j.euros.2023.03.009 · Cited by 10
PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer
Slootbeek, P. H. J., Overbeek, J. K., Ligtenberg, M. J. L., van Erp, N. P., & Mehra, N. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216367 · Cited by 10
Self-citation
SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP)
Cimadamore, A., Rescigno, P., Conteduca, V., Caliò, A., Allegritti, M., Calò, V., Montagnani, I., Lucianò, R., Patruno, M., Sergio Bracarda, A., et al. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03660-0 · Cited by 10
Safety and Efficacy of 177Lu-PSMA Therapy Following 223Radium Treatment: A Retrospective Multinational Real-World Analysis
Giannini, G., Kafka, M., Neuwirt, H., Artamonova, N., di Santo, G., Virgolini, I. J., Dotzauer, R., Deiss, E., Paffenholz, P., Heidenreich, A., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102260 · Cited by 9
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Matsubara, N., Azad, A., Agarwal, N., Fred Saad, C., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Jones, R. J., Zschäbitz, S., Oldenburg, J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00030-0 · Cited by 9
Self-citation
Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer
Hung, A., Candelieri-Surette, D., Li, Y., Alba, P. R., Robison, B., Agiri, F. Y., Perez, C., Lee, K., Maxwell, K. N., Li, W., et al. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.03.001 · Cited by 9
Is the Androgen Receptor a Viable Target in Triple Negative Breast Cancer in 5 Years?
Sharifi, M. N., O'Regan, R. M., & Wisinski, K. B. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.06.009 · Cited by 9
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation
Kaye, D. R., Khilfeh, I., Muser, E., Morrison, L., Kinkead, F., Urosevic, A., Lefèbvre, P., Pilon, D., & George, D. J. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2303890 · Cited by 9
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer
Anido, U., Calvo, O. F., Bañobre, J. R., Martínez-Breijo, S., Núñez, N. F., Seoane, Z. N., Pumar, M. G., Nebra, J. C., Garcia, G. M., Portela-Pereira, P., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1385466 · Cited by 9
Biomarker-Driven Oncology Trial Design and Subgroup Characterization: Challenges and Potential Solutions
Wang, J., Yu, B., Dou, Y. N., & Mascaro, J. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00116 · Cited by 10
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair Genes
Graham, L. S., Henderson, N., Kellezi, O., Hwang, C., Barata, P. C., Bilen, M. A., Kilari, D., Pierro, M. J., Thapa, B., Tripathi, A., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00014 · Cited by 9
Self-citation
Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate Cancer
Zacchi, F., Abida, W. M., Antonarakis, E. S., Bryce, A. H., Castro, E., Cheng, H. H., Shandhu, S., & Mateo, J. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.11.011 · Cited by 9
Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer
Calabrese, M., Saporita, I., Turco, F., Gillessen, S., Castro, E., Vogl, U. M., Stefano, R. F. D., Carfì, F. M., Poletto, S., Farinea, G., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010078 · Cited by 9
Blood-based liquid biopsy in advanced prostate cancer
Giunta, E. F., Malapelle, U., Russo, A. D., & Giorgi, U. D. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104241 · Cited by 9
A Cross-sectional Survey of Physicians to Understand Biomarker Testing and Treatment Patterns in Patients with Prostate Cancer in the USA, EU5, Japan, and China
Gratzke, C., Aggarwal, H., Kim, J., Chaignaud, H., & Oskar, S. (2024) · European Urology Open Science · doi:10.1016/j.euros.2024.07.113 · Cited by 8
‘Where is my gap’: mechanisms underpinning PARP inhibitor sensitivity in cancer
Buckley-Benbow, L., Agnarelli, A., & Bellelli, R. (2025) · Biochemical Society Transactions · doi:10.1042/bst20241633 · Cited by 8
Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe
Castro, E., Orji, C., Ribbands, A., Butcher, J., Walley, M., Li, W., & Ghate, S. R. (2025) · Future Oncology · doi:10.1080/14796694.2025.2470616 · Cited by 9
Recent advances in drug treatment for prostate cancer
Suzuki, K., Fujimoto, N., Shiota, M., Kawakami, S., Kimura, T., Hashimoto, K., Kosaka, T., Miyake, H., & Uemura, H. (2025) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01816-3 · Cited by 8
Optimizing treatment for metastatic castration‐resistant prostate cancer: Food and Drug Administration‐approved therapies, emerging strategies, and biomarker‐driven approaches
Saeed, F., Berchuck, J. E., Bilen, M. A., Gandhi, J. S., Nazha, B., Brown, J. T., Schuster, D. M., Jani, A. B., Yu, J., & Harik, L. R. (2025) · Cancer · doi:10.1002/cncr.70037 · Cited by 9
The interconnection between androgen receptor and DNA damage response pathways in prostate cancer
Sands, M., Adams, S. B., Lee, J., Li, M., Wang, M., Walsh, T., Leon, L., Zablah, A., Haerens, M., Liu, Z., et al. (2025) · Current Urology · doi:10.1097/cu9.0000000000000300 · Cited by 11
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States
Chehade, C. H., Özay, Z. İ., Jo, Y., Gebrael, G., Sayegh, N., Ostrowski, M., Srivastava, A., Garg, D., Hardy, T., Murdock, E. G., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.5585 · Cited by 8
Mechanistic Insights on Localized to Metastatic Prostate Cancer Transition and Therapeutic Opportunities
Yu, E.-M., Hwang, M. W., & Aragon‐Ching, J. B. (2023) · Research and Reports in Urology · doi:10.2147/rru.s386517 · Cited by 8
27-hydroxycholesterol and DNA damage repair: implication in prostate cancer
Galván, G. C., Friedrich, N. A., Das, S. K., Daniels, J. P., Pollan, S. G., Dambal, S., Suzuki, R., Sanders, S. E., You, S., Tanaka, H., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1251297 · Cited by 8
Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Santis, M. D., Breijo, S. M., Robinson, P. J., Capone, C., Pascoe, K. C., Sanden, S. V., Hashim, M., Trevisan, M., Daly, C., Reitsma, F., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02918-6 · Cited by 8
The Role of Liquid Biopsy in the Management of Patients with Genitourinary Malignancies
Maughan, B. L., Dyrskjøt, L., Grivas, P. D., Alcaraz, A., Antonarakis, E. S., Bilen, M. A., Bivalacqua, T. J., Cooperberg, M. R., Liang Cheng, C., & Gupta, S. (2025) · European Urology · doi:10.1016/j.eururo.2025.07.016 · Cited by 9
Pembrolizumab in mCRPC – Combination therapies as breakthrough to success?
Plas, S., Pircher, A., & Heidegger, I. M. (2023) · Current Opinion in Urology · doi:10.1097/mou.0000000000001121 · Cited by 8
Precision medicine for prostate cancer: An international perspective
Hamid, A., Sweeney, C. J., Hovens, C. M., Corcoran, N. M., & Azad, A. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.02.004 · Cited by 9
Clinician-Reported Management Recommendations in Response to Universal Germline Genetic Testing in Patients With Prostate Cancer
Shore, N. D., Pieczonka, C. M., Heron, S. P., Gazi, M., Cahn, D. B., Belkoff, L. H., Berger, A., Mazzarella, B. C., VEYS, J. A., Idom, C., et al. (2024) · The Journal of Urology · doi:10.1097/ju.0000000000004190 · Cited by 8
Self-citation
Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis
Maiorano, B. A., Catalano, M., Mercinelli, C., Cigliola, A., Tateo, V., Agarwal, N., Gupta, S., Roviello, G., & Necchi, A. (2025) · European Urology Open Science · doi:10.1016/j.euros.2024.12.008 · Cited by 7
Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01
Azad, A., Agarwal, N., Armstrong, A. J., Hellmis, E., Sugimoto, M., Ürün, Y., Xing, N., Aregay, M., Lima, J., Meulendijks, D., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2655433 · Cited by 8
Self-citation
Treatments and challenges in advanced prostate cancer
Gourdin, T. S., & Velayati, A. (2023) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000938 · Cited by 7
Treatment Landscape for Metastatic Castrate-Sensitive Prostate Cancer: A Review
Meagher, M. F., Salmasi, A., & Stewart, T. F. (2023) · Research and Reports in Urology · doi:10.2147/rru.s398129 · Cited by 7
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration’s Oncology Center of Excellence Project Optimus
Thall, P. F., Garrett-Mayer, E. S., Wages, N. A., Halabi, S., & Cheung, Y. K. (2024) · Clinical Trials · doi:10.1177/17407745241234652 · Cited by 7
Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches
Kopp, R. M., Aláez‐Verson, C., Angel, M. O., Delgado, A., Velho, P. I., Manduley, A., Tejado-Gallegos, L. F., Rodríguez, Y., Vargas, C., & Barata, P. C. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00628 · Cited by 7
Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review
Baboudjian, M., Peyrottes, A., Dariane, C., Fromont, G., Denis, J. A., Fiard, G., Kassab, D., Ladoire, S., Lehmann‐Che, J., Ploussard, G., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.05.003 · Cited by 7
New target therapies in prostate cancer: from radioligand therapy, to PARP-inhibitors and immunotherapy
Ceci, F., Farulla, L. S. A., Bonatto, E., Evangelista, L., Aliprandi, M., Cecchi, L. G., Mattana, F., Bertocchi, A., Vincenzo, F. D., Perrino, M., et al. (2024) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.24.03575-1 · Cited by 7
PARP inhibitor‐based treatment in metastatic, castration‐resistant prostate cancer (mCRPC): A systematic review and meta‐analysis
Roberto, M., Civita, M. A. D., Marinelli, D., Torchia, A., Cara, N., Maltese, G., Speranza, I., & Santini, D. (2025) · BJUI Compass · doi:10.1002/bco2.455 · Cited by 7
Empowering PARP inhibition through rational combination: Mechanisms of PARP inhibitors and combinations with a focus on the treatment of metastatic castration-resistant prostate cancer
Zhao, J., Tang, B., Shen, P., Zeng, H., & Wei, Q. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104698 · Cited by 7
Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
Kazmi, F., Shrestha, N., Liu, T. F. D., Foord, T. H., Heesen, P., Booth, S. W., Dodwell, D. J., Lord, S., Yeoh, K., & Blagden, S. P. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014872.pub2 · Cited by 8
BRCA and Beyond: Impact on Therapeutic Choices Across Cancer
Tan, J. S. H., Zhang, Z., Goh, H. X., & Ngeow, J. Y. Y. (2024) · Cancers · doi:10.3390/cancers17010008 · Cited by 8
Current androgen receptor antagonists under investigation for resistant prostate cancer: progress and challenges
Danielli, L., Tassinari, E., Marchetti, A., Rosellini, M., Mollica, V., Liang Cheng, C., & Massari, F. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2481141 · Cited by 6
Androgen receptor inhibition extends PARP inhibitor activity in prostate cancer models beyond BRCA mutations and defects in homologous recombination repair
Illuzzi, G., Galbiati, A., Staniszewska, A. D., Hanson, R., Michaloglou, C., Cooke, S. L., Uznańska, K., Białecka, M., Solarczyk, K. J., Dev, H., et al. (2025) · NAR Cancer · doi:10.1093/narcan/zcaf035 · Cited by 6
Research progress of DNA damage repair (DDR) and DDR inhibitors in tumor immunotherapy
Liu, Q., Zhang, C., Gao, Y., Feng, D., Deng, D., & Pan, Y. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-04101-9 · Cited by 7
Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial
Armstrong, A. J., Fred Saad, C., Oya, M., Shore, N. D., Procopio, G., Arslan, Ç., Mehra, N., Brown, E., Joung, J. Y., Sugimoto, M., et al. (2026) · JCO Precision Oncology · doi:10.1200/po-25-01109 · Cited by 6
Self-citation
Clinical actionability and utilization of next-generation sequencing for prostate cancer in a changing treatment landscape
Griffin, J. R., Tsao, C., Patel, V. G., Liaw, B. C.-H., Guin, S., Joshi, H. N., Rossi, M., Hantash, F. M., Zhou, X., Tewari, A., et al. (2022) · Frontiers in Urology · doi:10.3389/fruro.2022.997396 · Cited by 6
Precision Medicine in Castration-Resistant Prostate Cancer: Advances, Challenges, and the Landscape of PARPi Therapy—A Narrative Review
Dimitrov, G., Mangaldzhiev, R., Slavov, C., & Popov, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042184 · Cited by 6
Time-varying associations of patient and tumor characteristics with cancer survival: an analysis of SEER data across 14 cancer sites, 2004–2017
Roberts, E., Luo, L., Mondul, A. M., Banerjee, M., Veenstra, C. M., Mariotto, A. B., Schipper, M. J., He, K., Taylor, J. M. G., & Brouwer, A. F. (2024) · Cancer Causes & Control · doi:10.1007/s10552-024-01888-y · Cited by 6
Hormones as a double-edged sword: the role of hormones in cancer progression and the potential of targeted hormone therapies
Joshi, D., Patel, J., Munshi, M., Mistry, Z., Prajapati, A., Mukherjee, A., Ramachandran, A. V., Parashar, N. C., Parashar, G., Haque, S., et al. (2024) · Medical Oncology · doi:10.1007/s12032-024-02517-z · Cited by 6
PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells
Schaaf, Z. A., Ning, S., Leslie, A. R., Sharifi, M., Gao, R. Y., Maine, J. P., Lou, W., Lombard, A. P., Liu, C., Yu, A., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0339 · Cited by 6
Prostate cancer and genetic contributions
Chou, W. H., Chalker, C., Sokolova, A. O., & Isharwal, S. (2024) · Andrology · doi:10.1111/andr.13812 · Cited by 6
Clinical Application of PARP1 Inhibitors and Challenges in Cancer Therapy
Luo, Y., Nie, M., Chen, Y., Huang, X., Cui, X., Lin, W., Xu, L., Li, E., & Cheng, Y. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096327635241021115944 · Cited by 6
Implementing and Optimizing Universal Germline Genetic Testing for Patients With Prostate Cancer in Clinical Practice
Shore, N. D., Armstrong, A. J., Barata, P. C., Byrne, L., Hafron, J. M., Young, S., Paller, C. J., Wise, D. R., Ventii, K., Samadi, A., et al. (2025) · Urology · doi:10.1016/j.urology.2025.01.070 · Cited by 6
Self-citation
The PENDOR study: establishment of a panel of patient-derived tumor organoids from endometrial cancer to assess efficacy of PARP inhibitors
Gall, G. L., Cherifi, F., Divoux, J., Florent, R., Christy, F., Leconte, A., San, C., Devillers, A., Desmartin, G., Lecouflet, L., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13590-6 · Cited by 6
Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine
Wang, C., Han, X., Kong, S., Zhang, S., Ning, H., & Wu, F. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.117955 · Cited by 7
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
Fay, A. P., Fizazi, K. S., Matsubara, N., Azad, A., Fred Saad, C., Giorgi, U. D., Joung, J. Y., Fong, P. C. C., Jones, R. J., Zschäbitz, S., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00031-2 · Cited by 6
Self-citation
Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer
Gamba, T., Paparo, J., Panepinto, O., Dionisio, R., Maïo, M. D., & Vignani, F. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.07.009 · Cited by 6
PARP inhibitors in prostate cancers, is it time for combinations?
Teyssonneau, D., Dariane, C., Barret, É., Beauval, J., Brureau, L., Fiard, G., Fromont, G., Créhange, G., Gauthé, M., Ruffion, A., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241242959 · Cited by 6
Prostate cancer and novel pharmacological treatment options–what’s new for 2022?
Marchetti, A., Tassinari, E., Rosellini, M., Rizzo, A., Massari, F., & Mollica, V. (2023) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2023.2181783 · Cited by 8
Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study
Incorvaia, L., Puglisi, M., Maruzzo, M., Mammone, G., Caffo, O., Procopio, G., Antonuzzo, L., Rizzo, M., Conteduca, V., Messina, C. G. M., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf395 · Cited by 5
Self-citation
Unveiling the molecular profile of a prostate carcinoma: implications for personalized medicine
Agostini, M., Giacobbi, E., Servadei, F., Bischof, J., Funke, L., Sica, G. S., Rovella, V., Carilli, M., Iacovelli, V., Shi, Y., et al. (2024) · Biology Direct · doi:10.1186/s13062-024-00492-z · Cited by 5
BRCA Mutation Testing in Men With Metastatic Castration‐Resistant Prostate Cancer: Practical Guidance for Australian Clinical Practice
Azad, A., Gurney, H., Campbell, A., Goh, J. C. H., & Rathi, V. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14150 · Cited by 6
Integrating BRCA testing into routine prostate cancer care: a multidisciplinary approach by SIUrO and other Italian Scientific Societies
Mammone, G., Borghesi, S., Borsellino, N., Caliò, A., Ceccarelli, R., Cimadamore, A., Conti, G. N., Cortesi, L., D’Angelillo, R. M., Facchini, G., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-13521-5 · Cited by 5
Real-world treatment patterns and survival outcomes in men with metastatic castration-resistant prostate cancer in Finland: a national, population-based cohort study
Rannikko, A. S., Hölsä, O., Ågesen, T. H., Ekman, M., & Mattila, R. (2025) · Acta Oncologica · doi:10.2340/1651-226x.2025.42173 · Cited by 5
Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) Survey
Bitting, R. L., McNair, C. M., Wyatt, A. W., Vandekerkhove, G. R., Choi, T., Leader, A. E., Blanding-Godbolt, J., Gross, L., Hamade, K., Halabi, S., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00821 · Cited by 5
PARP inhibitors for HRR-deficient metastatic castration-resistant prostate cancer: mechanisms and clinical strategies
Peng, N., Chen, D., Yang, M., Zeng, C., & Li, W. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107193 · Cited by 6
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Smith, M. R., Piulats, J. M., Todenhöfer, T., Lee, J., Arija, J. Á. A., Mazilu, L., Azad, A., Alonso‐Gordoa, T., McGovern, U., Choudhury, A. D., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00475-9 · Cited by 5
Emerging systemic treatment for metastatic castration-resistant prostate cancer: a review of recent randomized controlled trials
Yanagisawa, T., Kawada, T., Rajwa, P., Kimura, T., & Shariat, S. F. (2023) · Current Opinion in Urology · doi:10.1097/mou.0000000000001080 · Cited by 5
Assessing olaparib efficacy in U.S. Veterans with metastatic prostate cancer utilizing a time-indifferent -rate method ideal for real-world analyses
Leuva, H., Zhou, M., Jamaleddine, N., Meseha, M., Faiena, I., Park, Y. A., McWilliams, G. W., Luhrs, C. A., Maxwell, K. N., Hoff, D. D. V., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105288 · Cited by 5

Authors: Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., de Menezes, J., Girotto, G., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlürmann, F., Joung, J. Y., Sugimoto, M., Virizuela, J. A., Emmenegger, U., Navratil, J., Buchschacher, G. L., Poehlein, C., Harrington, E. A., Desai, C., Kang, J., & Saad, F.
Affiliations: University of Manchester (GB)
Duke University (US)
Centre Hospitalier Universitaire de Besançon (FR)
Keio University (JP)
Carolina Urologic Research Center (US)
Centro de Investigaciones Clinicas Viña del Mar, Valparaíso, Chile
Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Hospital Nossa Senhora da Conceição (BR)
Hospital de Base (BR)
Izmir Economy University Medical Park Hospital, Karsiyaka, Turkey
Radboud University Medical Center (NL)
Ashford Cancer Centre Research, Adelaide, South Australia
University Hospital Southampton NHS Foundation Trust (GB)
Centre Hospitalier de Cornouaille (FR)
National Cancer Center (KR)
Kagawa University Hospital (JP)
Hospital Universitario Virgen Macarena (ES)
Sunnybrook Research Institute (CA)
Masaryk Memorial Cancer Institute, Brno, Czech Republic
Kaiser Permanente (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
AstraZeneca (United Kingdom) (GB)
AstraZeneca (United States) (US)
Centre Hospitalier de l’Universite de Montreal, Montreal
ORCID: Clarke, Noel W.
Armstrong, Andrew J.
Thiery-Vuillemin, Antoine
Oya, Mototsugu
Shore, Neal
Procopio, Giuseppe
Girotto, Gustavo
Mehra, Niven
Joung, Jae Y.
Sugimoto, Mikio
Virizuela, Juan A.
Emmenegger, Urban
Buchschacher, Gary L.
Poehlein, Christian
Harrington, Elizabeth A.
Kang, Jinyu
Venue: NEJM Evidence
Publisher: Massachusetts Medical Society
Published: 2022-08-23
Volume: 1
Issue: 9
Pages: EVIDoa2200043-EVIDoa2200043
ISSN: 2766-5526 (ISSN-L)
DOI: 10.1056/evidoa2200043
OpenAlex: W4281770555
Cited by: 426
References: 27
Citations by year: 2026: 77 · 2025: 108 · 2024: 111 · 2023: 110 · 2022: 20
FWCI: 56.30
Type: journal article
Language: en
Open access: closed
Locations: NEJM Evidence (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: abiraterone, olaparib, metastatic castration-resistant prostate cancer, PARP inhibitors, first-line therapy, homologous recombination deficiency, progression-free survival, overall survival, combination therapy, PARP inhibitor resistance, circulating tumor DNA, anemia, fatigue, nausea, hormone therapy
MeSH terms: Androstenes, Antineoplastic Combined Chemotherapy Protocols, Humans, Male, Phthalazines, Piperazines, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks